Clinical Trial Update: Lenvatinib and Capecitabine in Patients With Advanced Malignancies [Phase 1]

View source ↗

Summary

A Phase 1 study of lenvatinib in combination with capecitabine for patients with advanced cancers has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bone Cancer
• Brain Cancer
• Breast Cancer
• Gastrointestinal Cancer
• Gynecologic Cancer
• Lung Cancer
• Oral Cavity Cancer
• Urinary Tract Cancer

Drugs mentioned

• Capecitabine (capecitabine)
• LENVIMA (lenvatinib)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Advanced Cancer, Malignant Neoplasm of Breast | Phase 1 | Status: WITHDRAWN